Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia
Phase 2 Completed
Rituximab, Alemtuzumab, and GM-CSF As First-Line Therapy in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia
Phase 2 Completed
33 enrolled 12 charts
Chemotherapy and Peripheral Stem Cell Transplantation Followed by Immunotherapy in Treating Patients With Chronic Myelogenous Leukemia
Phase 2 Completed
22 enrolled
Interferon and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Patients With Chronic Phase CML on a TKI
Phase 2 Completed
36 enrolled 13 charts
Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Phase 2 Completed
26 enrolled 7 charts
Rituximab Plus Sargramostim (GM-CSF) In Patients With Chronic Lymphocytic Leukemia
Phase 2 Completed
130 enrolled 10 charts
CML0206
Phase 2 Completed
57 enrolled 5 charts
Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)
Phase 2 Terminated
5 enrolled 3 charts
Sargramostim in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission Following Initial Treatment
Phase 2 Completed
Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Myelodysplastic Syndrome (MDS) Relapse After Allogeneic Transplantation
Phase 2 Completed
15 enrolled 9 charts
Autologous Stem Cell Transplants for Chronic Myelogenous Leukemia
Phase 2 Withdrawn
Phenylbutyrate, Dexamethasone, and Sargramostim in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia
Phase 2 Completed
S9918 PSC 833, Daunorubicin, and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase 2 Completed
55 enrolled
S0112 Cytarabine and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia
Phase 2 Completed
71 enrolled
S0301 Cyclosporine, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
Phase 2 Completed
69 enrolled
Rituximab and GM-CSF in Treating Patients With Chronic Lymphocytic Leukemia
Phase 2 Terminated
Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase 2 Completed
41 enrolled 9 charts
Study of Azacytidine Followed by GM-CSF in Patients With Myelodysplastic Syndrome (MDS)
Phase 2 Terminated
8 enrolled 5 charts
Sargramostim After Bone Marrow Transplantation in Treating Patients With Myelodysplastic Syndrome
Phase 2 Completed
Bone Marrow Transplantation Plus Biological Therapy in Treating Patients With Chronic Myeloid Leukemia
Phase 2 Completed
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Relapsed Acute Lymphocytic Leukemia
Phase 2 Completed
30 enrolled
Combination Chemotherapy and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia
Phase 2 Completed
30 enrolled
Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer
Phase 2 Completed
40 enrolled
Immuno-Augmentation With GM-CSF of Pneumococcal Vaccine in Chronic Lymphocytic Leukemia Patients
Phase 2 Completed
39 enrolled 4 charts
Sargramostim Following Allogeneic Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia
Phase 2 Terminated
40 enrolled
Interferon Alfa Plus Sargramostim in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
Phase 2 Terminated
48 enrolled
Combination Chemotherapy Followed By Filgrastim or Sargramostim in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
Phase 2 Completed